Revised forecast
Fiscal year ending March 2027 · Full yearPrevious forecast published 14 May 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Shipments of semiconductor process materials are expected to increase in ICT & Mobility Solutions. In Essential & Green Materials, risks related to the uncertain business environment and other factors had been incorporated into the previous forecast, but business activities are progressing steadily. At Sumitomo Pharma, US sales are performing strongly, led by Gemtesa. As a result, revenue and core operating profit are expected to exceed the previous forecast, while operating profit and profit attributable to owners of the parent are also expected to exceed it due to the increase in core operating profit.
Business structure improvement expenses ¥5,003 million, impairment losses ¥4,178 million (interim period)
| Item | Details |
|---|---|
| Net Sales | ¥2,360,000 million → ¥2,490,000 million（5.5％） |
| Operating profit | ¥177,000 million → ¥215,000 million（21.5％） |
| Profit attributable to owners of the parent | ¥70,000 million → ¥90,000 million（28.6％） |
| Net income per share | 42.40 Yen/sen → 54.27 Yen/sen |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Full year |
| Publication date of previous forecast | 14 May 2026 |
| Previous-period results | Revenue ¥2,328,515 million, core operating profit ¥208,376 million, operating profit ¥151,744 million, profit attributable to owners of the parent ¥60,947 million, basic earnings per share ¥37.16 |
| Reason for the revision | Shipments of semiconductor process materials are expected to increase in ICT & Mobility Solutions. In Essential & Green Materials, risks related to the uncertain business environment and other factors had been incorporated into the previous forecast, but business activities are progressing steadily. At Sumitomo Pharma, US sales are performing strongly, led by Gemtesa. As a result, revenue and core operating profit are expected to exceed the previous forecast, while operating profit and profit attributable to owners of the parent are also expected to exceed it due to the increase in core operating profit. |
| Details and amount of extraordinary loss | Business structure improvement expenses ¥5,003 million, impairment losses ¥4,178 million (interim period) |
| Dividend forecast revision | For the fiscal year ending March 2027: interim ¥8.00, year-end ¥9.00, annual ¥17.00. The dividend forecast has been revised from the most recently announced forecast. The amount and direction before revision were Not disclosed. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Shipments of semiconductor process materials are expected to increase in ICT & Mobility Solutions; in Essential & Green Materials, business activities are progressing steadily against the risks factored in based on the uncertain business environment; and US sales at Sumitomo Pharma are performing strongly, led by Gemtesa.